| Literature DB >> 29637819 |
Ashim Dey1, Abby L Manthey2, Kin Chiu2,3,4, Chi-Wai Do1.
Abstract
Glaucoma, a form of progressive optic neuropathy, is the second leading cause of blindness worldwide. Being a prominent disease affecting vision, substantial efforts are being made to better understand glaucoma pathogenesis and to develop novel treatment options including neuroprotective and neuroregenerative approaches. Cell transplantation has the potential to play a neuroprotective and/or neuroregenerative role for various ocular cell types (e.g., retinal cells, trabecular meshwork). Notably, glaucoma is often associated with elevated intraocular pressure, and over the past 2 decades, several rodent models of chronic ocular hypertension (COH) have been developed that reflect these changes in pressure. However, the underlying pathophysiology of glaucoma in these models and how they compare to the human condition remains unclear. This limitation is the primary barrier for using rodent models to develop novel therapies to manage glaucoma and glaucoma-related blindness. Here, we review the current techniques used to induce COH-related glaucoma in various rodent models, focusing on the strengths and weaknesses of the each, in order to provide a more complete understanding of how these models can be best utilized. To so do, we have separated them based on the target tissue (pre-trabecular, trabecular, and post-trabecular) in order to provide the reader with an encompassing reference describing the most appropriate rodent COH models for their research. We begin with an initial overview of the current use of these models in the evaluation of cell transplantation therapies.Entities:
Keywords: chronic ocular hypertension; glaucoma; rodent models
Mesh:
Substances:
Year: 2018 PMID: 29637819 PMCID: PMC5898687 DOI: 10.1177/0963689717724793
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064
Figure 1.Schematic diagram illustrating the structure of whole eye (left) and anterior segment (right). During the conventional outflow pathway, aqueous humor is produced by the ciliary body and it flows from the posterior chamber through the pupil into the anterior chamber (shown by continuous lines with arrowheads). It then flows out through the trabecular meshwork into Schlemm’s canal and is subsequently absorbed into the episcleral veins via the collector channels. In the unconventional outflow pathway, aqueous humor flows out from anterior chamber through the face of the ciliary body and iris root to the ciliary muscle and suprachoroidal space to either veins in the choroid and sclera or through scleral pores to episcleral tissue (shown by dashed lines and arrowheads).
Effect of Volume and Bead Size on the Ability of an Injected Substance to Elevate IOP.
| Injected Substance | Species | Bead Size (µm) | Total Volume (µL) | Duration (wk) | C_Mean IOP (mmHg) | G_Mean IOP (mmHg) | ERG | RGCs Loss % | Axon Loss % | Remarks | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HA | Wistar rats | 25 | 1* | 11.9 ± 0.7 | 15.5 ± 1.0 | *8 d, Weekly repeated injection can sustain IOP for 10 wk |
[ | ||||
| Latex microsphere | SD rats | 10 | 20 | 30 | 23.06 ± 0.8 | 28.1 ± 0.7 | 23.1 | Weekly 9 injections required to sustain high IOP |
[ | ||
| Latex microsphere + HPM | 10 | 20 (10 + 10) | 30 | 23.06 ± 0.8 | 31.1 ± 0.6 | 27.2 | Weekly 6 injections required to sustain high IOP | ||||
| Polystyrene beads | BN rats | 15 | 2.5 | 2** | 21.4 ± 0.95 | 26.9 | **13 d, ***10 d |
[ | |||
| 15 | 5 | 2 | 21.3 ± 1.3 | 28.8 | |||||||
| 15 | 7 | 1.5*** | 21.3 ± 0.96 | 29.7 | |||||||
| C57BL/6 mice | 15 | 1 | 3 | 15.3 ± 0.08 | 20.0 ± 0.8 | ||||||
| HA + Polystyrene beads | C57/BL6 (younger#/older##) | 6 | 5 (3 + 2) | 12 | 9.8 ± 1.0 | 14.4 ± 4.0 | 5.2 | 6.5 | #8-wk-old rats, 13.6% increase in AXL postbred injection |
[ | |
| 6 | 5 (3 + 2) | 12 | 11.2 ± 0.8 | 16.4 ± 2.5 | 4.1 | 0.1 | ##8-mo-old rats, 8.3% increase in AXL postbred injection | ||||
| DBA/2J mice | 6 | 5 (3 + 2) | 12 | 10.7 ± 0.9 | 13.0 ± 2.6 | 4.1 | 13.9 | 8.7% increase in AXL postbred injection | |||
| CD1 mice | 6 | 5 (3 + 2) | 12 | 10.3 ± 0.8 | 13.5 ± 3.2 | 20.1 | 32 | 4.3% increase in AXL postbred injection | |||
| Mice¥ | 6 + 1 | 5 (1 + 2 + 2) | 6 | 31 | ¥B6.Cg-Tg (Thy1-YFPH)2Jrs/J |
[ | |||||
| Visco + Polystyrene beads | C57BL/6 mice | 6 | 5 (3 + 2) | 6 | 9.8 ± 1.1 | 15.3 ± 4.6 | 16 | 7% increase in AXL postinjection |
[ | ||
| 6 + 1 | 5 (1 + 2 + 2) | 6 | 10.2 ± 0.8 | 18.6 ± 3.2 | 10 | ||||||
| CD1 mice | 6 | 5 (3 + 2) | 6 | 10.3 ± 1.8 | 11.8 ± 2.0 | 7 | |||||
| 6 + 1 | 5 (1 + 2 + 2) | 6 | 13.5 ± 1.4 | 21.6 ± 4.9 | 42 | ||||||
| 6 + 1 | 5 (2 + 1.5 + 1.5) | 6 | 10.4 ± 0.9 | 12.9 ± 2.7 | 23 | ||||||
| Polystyrene beads | C57Bl/6mice | 6 + 1 | 5 (3 + 2) | 12 | 12.3 ± 3.3 | 15.6 ± 5.5 | ↓pSTR | 11.2 | Increase in AXL |
[ | |
| Visco + Polystyrene beads | Wistar rats | 6 + 10 | 15 (5 + 5 + 5) | 6 | 11.4 ± 0.8 | 30.9 ± 3.2 | 34 | 25 | Increase in AXL was not reported |
[ | |
| HA + Polystyrene beads | C57Bl/6Jmice | 6 + 1 | 3 + 1.5 | 24 | 10.6 ± 2.8 | 13.1 ± 4.1 | ↓pSTR | 14.4 | Increase in AXL |
[ | |
| Magnetic beads | BN rats | 5 | 10 − 20 | 4 | 23.6 ± 0.4 | 29.4 ± 0.9 | 36.4 | Weekly repeated injection (3) |
[ | ||
| AS rats | 5 | 20 | 4 | 24.59 ± 0.42 | 28.15 ± 4.37 | 80.3 | Peak IOP 43.05 ± 2.33 at 1 wk |
[ |
Abbreviations: IOP, intraocular pressure; C_Mean IOP, control eyes_mean IOP; G_Mean IOP, glaucoma eyes_mean IOP; ERG, electroretinogram; RGCs, retinal ganglion cells; HA, hyaluronic acid; HPM, hydroxypropylmethylcellulose; SD rats, Sprague-Dawley rats; BN rats, Brown-Norway rats; AS rats, Albino Swiss rats; AXL, axial length; pSTR, positive scotopic threshold response.
*,**,*** Represent the duration of sustained IOP elevation (in days/wk) for a single intervention.
#,##Represents the age of the mice and ¥denotes the detail of the mutant mice.
Overview of Laser-induced COH Rodent Models.
| Anatomical Position of Laser Treatment | Type of Laser | Animal | Duration (wk) | C_Mean IOP (mmHg) | G_Mean IOP(mmHg) | RGC Loss (%) | Axon Loss (%) | ERG | Remarks | References |
|---|---|---|---|---|---|---|---|---|---|---|
| TM | Argon laser | WK rats | 5 | Injected Indian ink 1 wk prior to laser |
[ | |||||
| Diode laser | Wistar rats | 9 | 19.2 ± 0.9 | 22.0 ± 1.8 | 48.4 | Laser power: 0.4 W, duration: 0.7 s |
[ | |||
| TM + episcleral veins | Diode laser | Wistar rats | 9 | 19.8 ± 1.6 | 25.5 ± 2.9 | 70.9 | Laser power: 0.4 W, duration: 0.7 s | |||
| 9 | 19.5 ± 1.3 | 22.7 ± 3.4 | 49.7 | Laser power: 0.6 W, duration: 0.5 s | ||||||
| C57/BL6 mice | 4 | 15.8 ± 0.8 | 27.4 ± 1.2 | Amplitude of a-, b-wave, and OP ↓ | Injected indocyanine green into AC 20 min prior to laser treatment |
[ | ||||
| 8 | 17.3 ± 0.7 | 19.5 ± 0.9 | ||||||||
| Limbus | Diode laser | BS mice | 12 | 16.2 ± 2.4 | 20.1 ± 3.5 | AC was flattened by aspirated AH |
[ | |||
| 12 | 15.3 ± 2.0 | 19.4 ± 3.9 | 63.1 | Loss of axons are proportion to the magnitude and duration of elevated IOP |
[ | |||||
| Limbal + episcleral veins | Diode laser | Wistar rats | 9 | 19.3 ± 3.1 | 19.0 ± 4.2 | 4.6 | Laser power: 1 W, duration: 0.2 s |
[ | ||
| Argon laser | Wistar rats | 8 | 16.0 ± 0.4 | 27.9 ± 0.6 | 33 | Mean loss of 5.5% per week |
[ | |||
| 3 | 16 | 32 | 28 | Memantine can significantly reduce the loss of RGCs compare to vehicle treated. |
[ | |||||
| Lewis rats | 3 | 15.8 ± 0.2 | 30.4 ± 0.42 | 0.28 | Sustained IOP for at least 3 wk |
[ | ||||
| SD rats | 5 | 11 | 23.6 | 29.8 | 2.4 times increased of NO production |
[ | ||||
| 4 | 14.9 ± 3.1 | 20.7 ± 2.6 | 21.7 | 12.6% loss of RGC at 2 wk time point |
[ | |||||
| 4 | 17.5 ± 3.70 | 26.75 ± 2.75 | N1, P1 amplitude ↓; N/P ratio↑ | Multifocal ERG was performed |
[ | |||||
| 4 | 13.4 ± 0.7 | 22.1 ± 1.1 | 21.1 | 17% loss of RGC at 2 wk time point |
[ | |||||
| 2 | 13.3 ± 0.7 | 24.5 ± 0.8 | 17.7 | ‘betaB2-crystallin’ was neuroprotective to RGCs |
[ | |||||
| C57BL/6J mice | 4 | 11.2 ± 0.67 | 20.0 ± 2.8 | 27.3 | Modified Schiotz-indentation tonometer were used to evaluate IOP |
[ | ||||
| 8 | 17.0 ± 2.2 | |||||||||
| 4 | 13 ± 1.8 | 20.0 ± 2.8 | 22.4 | IOP raised in 90% treated eyes |
[ |
Abbreviations: COH, chronic ocular hypertension; IOP, intraocular pressure; C_Mean IOP, control eyes_mean IOP; G_Mean IOP, glaucoma eyes_mean IOP; TM, trabecular meshwork; WK, Wistar Kyoto rats; BS mice, Black Swiss mice; SD rats, Sprague-Dawley rats; AC, anterior chamber; AH, aqueous humor; OP, oscillatory potentials; NO, nitric oxide; RGCs, retinal ganglion cells.
Overview of Various Methods to Induce COH.
| Level of Intervention | Procedure | Species | Specialized Material/Instruments | Expertise | Expense* | References | |
|---|---|---|---|---|---|---|---|
| Invasive | Pre-trabecular | HA injection | Rat/mice | Hyaluronic acid | Micro surgery | + |
[ |
| Microbeads | Rat/mice | Microbeads | + |
[ | |||
| Magnetic microbeads | Rat/mice | Magnetic beads, magnet | + |
[ | |||
| Trabecular | Viral vectors injection | Rat/mice | Viral vectors | Micro surgery | ++ |
[ | |
| Laser on TM | Rat/mice | Laser machine | Laser operation | ++ |
[ | ||
| Post-trabecular | Laser on limbal and episcleral veins | Rat/mice | Laser machine | Laser operation | ++ |
[ | |
| Cauterization of episcleral veins | Rat/mice | Cautery | Micro surgery | + |
[ | ||
| ligation of episcleral veins | Rat/mice | 10-0/11-0 nylon suture | + |
[ | |||
| Hypertonic saline injection into episcleral veins | Rat/mice | Customized plastic ring | + |
[ | |||
| Circumlimbal suture | Rat/mice | 8-0 nylon suture | + |
[ | |||
| Combination of Trabecular and post-trabecular | Laser on TM + Episcleral veins | Rat/mice | Laser machine | Laser operation | ++ |
[ | |
| Noninvasive | Topical corticosteroid | Rat/mice | Steroid drops | NA | NA |
[ | |
Abbreviations: COH, chronic ocular hypertension; TM, trabecular meshwork; NA, not applicable; +, relatively mild expensive; ++, relatively moderate to high expensive.
*Relative expense.